What is Form Bio?
Form Bio operates at the intersection of artificial intelligence and biotechnology, focusing on the optimization of genetic medicine. The company provides a sophisticated platform designed to streamline the development of AAV vectors and enhance the precision of CRISPR-based editing tools. By addressing fundamental challenges in genome integrity and protein engineering, Form Bio enables researchers to navigate the complex transition from conceptual design to clinical application.
The company's market position is defined by its specialized service offerings, which cater to the growing demand for safer, more efficient genetic therapies. Through its proprietary AI-driven solutions, Form Bio effectively reduces the time and cost associated with therapeutic discovery, establishing itself as an essential partner for biotech firms aiming to modernize their R&D workflows.
How much funding has Form Bio raised?
Form Bio has raised a total of $30M across 1 funding round:
Series A
$30M
Series A (2022): $30M with participation from JAZZ Venture Partners and Thomas Tull
Key Investors in Form Bio
JAZZ Venture Partners
JAZZ Venture Partners is a venture capital firm that invests in technologies aimed at enhancing human performance across various sectors, including healthcare, wellness, and consumer markets.
Thomas Tull
Thomas Tull is a prominent investor and entrepreneur known for his strategic backing of high-growth technology and media ventures.
What's next for Form Bio?
With this major enterprise-level funding, Form Bio is poised to expand its operational capacity and deepen its investment in proprietary AI models. The strategic roadmap likely includes the scaling of its vector and payload design services, alongside the expansion of its next-generation editing toolset. As the firm continues to refine its platform, the focus will shift toward establishing broader industry partnerships and accelerating the clinical validation of its genetic medicine solutions.
The company's trajectory suggests a long-term commitment to solving the most persistent bottlenecks in genome engineering. By maintaining a focus on high-accuracy, data-backed therapeutic development, Form Bio is well-positioned to capture significant market share as the global demand for personalized genetic medicine continues to rise.
